Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
Date:3/12/2008

s in salaries and related personnel costs (including an increase of $1.5 million in stock-based compensation charges) from the planned addition of general and administrative staff in 2007 as compared to 2006, and costs related to operating as a public company.

Financial Outlook for 2008

Cadence currently anticipates that total operating expenses for full year 2008 will be between $54 million and $59 million including an estimated $4 to $6 million in non-cash stock-based compensation expenses. Cadence expects that cash, cash equivalents and investments held for sale at December 31, 2008, will be between $41 million and $46 million.

Acetavance(TM) Clinical Program

-- In January 2008, Cadence announced topline results from two Phase III

clinical trials of Acetavance, Study 301 and Study 302. While Study

301, which evaluated Acetavance in the treatment of pain following

abdominal gynecologic surgery, successfully achieved several secondary

endpoints, including pain relief, global patient satisfaction and time

to administration of rescue medication, the study did not meet its

primary endpoint of demonstrating a statistically significant reduction

in patients' pain intensity levels over 48 hours compared to placebo.

Study 302, a Phase III clinical trial of Acetavance in fever,

successfully met its primary endpoint, demonstrating a statistically

significant reduction of fever over six hours compared to placebo. In

both studies, Acetavance demonstrated a favorable safety profile, which

was similar to placebo.

-- In January 2008, Cadence also initiated communications with the FDA to

obtain additional guidance regarding its clinical development program

for Acetavance. Cadence expects to receive such guidance from the FDA

in the second quarter of 2008. Based upon the outcome of these

communicatio
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
2. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
3. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
4. SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results
5. Onyx Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
6. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
7. Drinking Water Association Discusses Pharmaceuticals in Water
8. Genesis Pharmaceuticals Changes Auditors
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
11. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... An inspiring story of the importance ... the season finale of “Extreme Weight Loss” Season Four. ... daughter from Highlands Ranch, Colo. who have a strained ... pounds. Their challenge is to team up to lose ... non-competitive approach to weight loss transformations, “Extreme Weight Loss” ...
(Date:9/3/2014)... 03, 2014 Health information technology ... safety, decreases medical errors, and strengthens the interaction ... mark the important role health information technology plays ... others across the U.S. have joined together to ... September 16-20, 2014. With the NHIT Week theme: ...
(Date:9/3/2014)... (PRWEB) September 03, 2014 Independent ... use of appropriate evidence-based health care along the ... benefit from the expertise of accredited independent review ... health care system. , As a core function, ... often settle questions of medical necessity. Yet backed ...
(Date:9/2/2014)... IMCA Speedway Motors Super Nationals, presented by Casey’s ... at the IMCA Speedway in Boone, Iowa. On ... check presentation to Hope For The Warriors® ( http://www.hopeforthewarriors.org ... organization that assists post-9/11 service members, their families, and ... psychological wounds in the line of duty. ...
(Date:9/2/2014)... PULLMAN, Wash. - Smoking today,s concentrated pot might ... research from Washington State University. The study is ... development of tolerance to THC. , Psychology ... estrogen levels, female rats are at least 30 ... qualities of THCthe key active ingredient in cannabis. ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Independent Review Expands Its Scope: Case Studies in Context 2Health News:Independent Review Expands Its Scope: Case Studies in Context 3Health News:IMCA to Present Donation to Hope For The Warriors 2Health News:Estrogen increases cannabis sensitivity 2Health News:Estrogen increases cannabis sensitivity 3
... , , ATLANTA, ... related to the diagnosis and treatment of infertility with ovulation induction ... emotional, scientific and financial aspects. Discussions include information about age related ... donor sperm or donor eggs. , , ...
... , , ... officials announced today that Tennessee residents have saved over $7.3 million ... the free statewide prescription assistance program. Tennessee Drug Card, which ... 2007. The program has no restrictions to membership, no income requirements, ...
... , , MINNEAPOLIS, July 27 ... world,s population, often resulting in patches of dry skin, and little red ... the teenage years but may continue throughout adulthood. There is no ... B. Fleischer, professor and chair of the department of dermatology at Wake ...
... exercise at lower concentrations , MONDAY, July 27 (HealthDay ... have a negative effect on lung function in healthy people, ... allows for ozone concentrations of up to 75 parts per ... that 6.6 hours exposure to mean ozone concentrations as low ...
... , LA JOLLA, Calif., July 27 For the ... business leaders, community members and cancer survivors "surfing for a cure" ... held at UC San Diego,s Scripps Institution of Oceanography. Now, members ... Longboard Invitational portion of the event that takes place on Sunday, ...
... New York, NY The Lymphoma Research Foundation (LRF) is ... Research Foundation Clinical Investigator Career Development Award has been ... the Nebraska Medical Center in Omaha, Nebraska. ... is broadly categorized into Hodgkin lymphoma (HL) and non-Hodgkin ...
Cached Medicine News:Health News:Tennessee Drug Card Has Saved Residents Over $7.3 Million 2Health News:What Is Keratosis Pilaris (KP)? 2Health News:'Safe' Ozone Levels May Not Be for Some 2Health News:Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 16 Years of 'Surfing for a Cure' to Raise Funds for Cancer Research 2Health News:Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 16 Years of 'Surfing for a Cure' to Raise Funds for Cancer Research 3Health News:Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 16 Years of 'Surfing for a Cure' to Raise Funds for Cancer Research 4Health News:Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research 2
(Date:9/2/2014)... BARCELONA, Spain , September 2, 2014 ... treatment decisions, including patients, quality of life and treatment ... [ 2 ]   ... ESC Congress 2014, 02 September 2014, ... year results of the PREvention oF thromboembolic events-European Registry ...
(Date:9/2/2014)... , Sept. 2, 2014  Edison Nation Medical, ... partnership with the American Association for Respiratory Care ... respiratory care specialists. Edison Nation Medical, which brings ... business to commercialize their innovation ideas, will work ... of more than 50,000 respiratory therapists in bringing ...
(Date:9/2/2014)... 2, 2014  EMD Serono, Inc., a subsidiary of ... today that Drew Young has joined the ... this capacity, he will be responsible for leading the ... including future products.   Bringing more than 20 ... sales efforts at pharmaceutical and biotech companies, Mr. Young ...
Breaking Medicine Technology:One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4
... presented at the 10th International Kidney Cancer Symposium ... pretreatment blood-based test, VeriStrat, was able to stratify ... combination of two targeted therapies, sunitinib (Sutent®) and ... tested VeriStrat Good had significantly longer progression free ...
... 14, 2011 Reata Pharmaceuticals, Inc. announced Friday a ... company,s lead program, bardoxolone methyl, and to continue advancing ... the following executives: Paul Audhya, MD, ... Hilary Malone, Ph.D., as Vice President and ...
Cached Medicine Technology:VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 2VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 3Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 2Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 3
... Insulin-like growth factor II (IGF-II) is a ... the liver and is postulated to have mitogenic ... actions of IGF-II are mediated by binding to ... to the Type II IGF receptor, a monomeric ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... known as Anti-Mullerian Inhibiting Substance (AMH), is ... kDa monomers linked by disulfide bridges (1). ... (TGF-?) superfamily which includes TGF-? and the ... members of this superfamily are dimeric glycoproteins, ...
Medicine Products: